3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
88
Leukemia, Myeloid, Acute
34
Leukemia
32
Myelodysplastic Syndromes
22
Lymphoma, Follicular
18
Lymphoma, Non-Hodgkin
16
Lymphoma, B-Cell, Marginal Zone
16
Lymphoma
16
Lymphoma, Mantle-Cell
15
Lymphoma, Large B-Cell, Diffuse
12
Waldenstrom Macroglobulinemia
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Multiple Myeloma
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Leukemia, Myelomonocytic, Chronic
9
Burkitt Lymphoma
9
Hematologic Neoplasms
8
Recurrence
7
Lymphoma, T-Cell, Peripheral
7
Lymphoma, Large-Cell, Immunoblastic
7
Leukemia, Plasma Cell
7
Lymphoma, Large-Cell, Anaplastic
6
Leukemia, B-Cell
6
Immunoblastic Lymphadenopathy
6
Hodgkin Disease
6
Sezary Syndrome
5
Mycosis Fungoides
5
Leukemia, Hairy Cell
5
Intraocular Lymphoma
5
Anemia
5
Interventions
Cyclophosphamide
8
fludarabine phosphate
7
fludarabine
6
Busulfan
5
Tacrolimus
4
Mycophenolic Acid
4
ponatinib
2
ibrutinib
2
Whole-Body Irradiation
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mesna
2
Melphalan
2
Bone Marrow Transplantation
2
Bendamustine Hydrochloride
2
AP 1903 reagent
2
thymoglobulin
1
tetulomab tetraxetan lu-177
1
durvalumab
1
Rituximab
1
Pharmacogenomic Testing
1
Lymphocyte Depletion
1
Lutetium-177
1
Lutetium
1
Lenalidomide
1
KW-2478
1
Imatinib Mesylate
1
Hsp90 inhibitor KU757
1
CA-4948
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Immune System Diseases
×
Lenalidomide
×
Other hematologic neoplasm
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts